Item no. |
HY-15306A-10mM |
Manufacturer |
MedChem Express
|
CASRN |
496775-62-3 |
Amount |
10mM/1mL |
Quantity options |
100 mg
10mM/1mL
10 mg
50 mg
5 mg
|
Category |
|
Type |
Inhibitors |
Specific against |
other |
Purity |
99.96 |
Formula |
C29H36N6O6 |
Citations |
Eur J Clin Pharmacol. 2022 Aug 3. Front Pharmacol. 2020 Nov 16;11:582625. Alzheimers Res Ther. 2024 Jun 3;16(1):121. Blood Adv. 2017 Feb 28;1(7):468-476. BMC Cancer. 2020 Nov 30;20(1):1171. Cells. 2022, 11(3), 319. Curr Microbiol. 2021 Feb 21. J Pharm Biomed Anal. 235, 25 October 2023, 115683 J Thromb Haemost. 2022 May 27. Virology. 2023 Jun 21. Viruses. 2019 Apr 25;11(4):385. [1]Erickson-Miller CL, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009 Feb;27(2):424-30. [2]Erickson-Miller CL, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005 Jan;33(1):85-93. [3]Lee H, et al. Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections. Antibiotics (Basel). 2021 Nov 9;10(11):1372. [4]Juan Zhu, et al. Identification of Eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms. Curr Microbiol. 2021 Feb 21. [5]Kurokawa T, et al. The Eltrombopag antitumor effect on hepatocellular carcinoma. Int J Oncol. 2015 Nov;47(5):1696-702. |
Smiles |
O=C(C1=CC(C2=CC=CC(N/N=C3C(C)=NN(C4=CC=C(C)C(C)=C4)C/3=O)=C2O)=CC=C1)O.NCCO.NCCO |
ECLASS 10.1 |
32160490 |
ECLASS 11.0 |
32160490 |
UNSPSC |
12000000 |
Alias |
Eltrombopag diethanolamine salt; SB-497115GR |
Available |
|
Product Description |
Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well[1][2][3][4][5]. |
StorageTemperature |
4°C (Powder, sealed storage, away from moisture) |
Shipping |
Room Temperature |
Manufacturers Applications |
COVID-19-immunoregulation |
MolecularWeight |
564.63 |
Clinical Information |
Launched |
Manufacturers Research Area |
Cancer; Infection; Cardiovascular Disease |
Solubility |
DMSO : ≥ 50 mg/mL |
Target |
Apoptosis; Bacterial; Thrombopoietin Receptor |
Manufacturers Target |
Apoptosis; Bacterial; Thrombopoietin Receptor |
Manufacturers Pathway |
Anti-infection; Apoptosis; Immunology/Inflammation |
Manufacturers Product type |
Reference compound |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.